Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations
- PMID: 1924299
- PMCID: PMC52517
- DOI: 10.1073/pnas.88.19.8405
Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations
Abstract
At present, mutation of the p53 gene appears to be the most common genetic alteration found in human cancers. These mutations can occur within many different regions of the gene. We have developed a modification of denaturing gradient gel electrophoresis termed "constant denaturant gel electrophoresis" (CDGE), which provides a rapid and sensitive method to screen the four conserved regions within the p53 gene where the majority of p53 mutations have been reported. The sensitivity of CDGE was first tested with known p53 mutations in all four conserved regions. The CDGE technique was then used to screen 32 breast carcinomas that had been analyzed by immunohistochemical methods for altered p53 protein levels and whose DNA had already been shown to have loss of heterozygosity for a chromosome 17p marker. By immunostaining techniques, only 6 of the 32 tumors had elevated p53 expression. However, CDGE detected p53 mutations in 11 of the 32 tumors. DNA sequence analysis was performed to determine the nucleotide positions of these mutations in all 11 samples. Loss of heterozygosity for the pYNZ22 or p144D6 markers did not associate with either the loss of heterozygosity at the p53 locus or the mutations detected by CDGE. We conclude that CDGE is a rapid and effective technique to screen for p53 mutations.
Similar articles
-
Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE).Hum Mutat. 1993;2(4):274-85. doi: 10.1002/humu.1380020407. Hum Mutat. 1993. PMID: 8401536
-
Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Advantages of using constant denaturant gel electrophoresis in mutation detection.Diagn Mol Pathol. 1995 Sep;4(3):203-11. doi: 10.1097/00019606-199509000-00008. Diagn Mol Pathol. 1995. PMID: 7493140
-
Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.Cancer Res. 1993 Apr 1;53(7):1637-41. Cancer Res. 1993. PMID: 8453635
-
Screening for mutations in human HPRT cDNA using the polymerase chain reaction (PCR) in combination with constant denaturant gel electrophoresis (CDGE).Mutat Res. 1992 Sep;269(1):41-53. doi: 10.1016/0027-5107(92)90159-y. Mutat Res. 1992. PMID: 1381470
-
Detection of DNA variation in cancer.Pharmacogenetics. 1992 Dec;2(6):317-28. doi: 10.1097/00008571-199212000-00011. Pharmacogenetics. 1992. PMID: 1306133 Review.
Cited by
-
Immunohistochemical assessment of primary breast tumors and metachronous brain metastases, with particular regard to differences in the expression of biological markers and prognosis.Exp Ther Med. 2010 Jul;1(4):561-567. doi: 10.3892/etm_00000088. Epub 2010 Jul 1. Exp Ther Med. 2010. PMID: 22993576 Free PMC article.
-
Improved mutation detection in GC-rich DNA fragments by combined DGGE and CDGE.Nucleic Acids Res. 1999 Aug 1;27(15):e9. doi: 10.1093/nar/27.15.e9. Nucleic Acids Res. 1999. PMID: 10454628 Free PMC article.
-
p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival.Br J Cancer. 1999 Feb;79(5-6):895-902. doi: 10.1038/sj.bjc.6690143. Br J Cancer. 1999. PMID: 10070887 Free PMC article.
-
Tumor-suppressor genes: cardinal factors in inherited predisposition to human cancers.Environ Health Perspect. 1992 Nov;98:25-37. doi: 10.1289/ehp.929825. Environ Health Perspect. 1992. PMID: 1336726 Free PMC article. Review.
-
p53 mutations and overexpression in locally advanced breast cancers.Br J Cancer. 1994 Jun;69(6):1145-50. doi: 10.1038/bjc.1994.225. Br J Cancer. 1994. PMID: 8198984 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous